RSS feed

Publications by Elisabeth Emilsen

18 publications found

Original articles

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111

Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B (2016)
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471

Magnussen GI, Emilsen E, Giller Fleten K, Engesæter B, Nähse-Kumpf V, Fjær R, Slipicevic A, Flørenes VA (2015)
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
BMC Cancer, 15, 462
DOI 10.1186/s12885-015-1474-8, PubMed 26054341

Flørenes VA, Emilsen E, Dong HP, Førsund M, Holm R, Slipicevic A (2015)
Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma
Cancer Med, 4 (6), 903-13
DOI 10.1002/cam4.425, PubMed 25663244

Slipicevic A, Øy GF, Rosnes AK, Stakkestad Ø, Emilsen E, Engesæter B, Mælandsmo GM, Flørenes VA (2012)
Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis
Cancer Biol Ther, 14 (2), 146-54
DOI 10.4161/cbt.22953, PubMed 23192275

Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B (2012)
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154

Magnussen GI, Ree Rosnes AK, Shahzidi S, Dong HP, Emilsen E, Engesæter B, Flørenes VA (2012)
Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma
Biochem Biophys Res Commun, 420 (3), 516-22
DOI 10.1016/j.bbrc.2012.03.023, PubMed 22446330

Slipicevic A, Holm R, Emilsen E, Ree Rosnes AK, Welch DR, Mælandsmo GM, Flørenes VA (2012)
Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival
BMC Cancer, 12, 73
DOI 10.1186/1471-2407-12-73, PubMed 22356677

Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A, Flørenes VA (2012)
High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy
PLoS One, 7 (6), e38254
DOI 10.1371/journal.pone.0038254, PubMed 22719872

Dong HP, Holth A, Ruud MG, Emilsen E, Risberg B, Davidson B (2010)
Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays
Cytopathology, 22 (6), 365-72
DOI 10.1111/j.1365-2303.2010.00811.x, PubMed 21054589

Hjortland GO, Bjørnland K, Pettersen S, Garman-Vik SS, Emilsen E, Nesland JM, Fodstad O, Engebraaten O (2003)
Modulation of glioma cell invasion and motility by adenoviral gene transfer of PAI-1
Clin Exp Metastasis, 20 (4), 301-9
DOI 10.1023/a:1024040718238, PubMed 12856717

Lorico A, Nesland J, Emilsen E, Fodstad O, Rappa G (2002)
Role of the multidrug resistance protein 1 gene in the carcinogenicity of aflatoxin B1: investigations using mrp1-null mice
Toxicology, 171 (2-3), 201-5
DOI 10.1016/s0300-483x(01)00584-4, PubMed 11836025

Wiatrowska BA, Berner A, Torlakovic G, Emilsen E, Mykelbost GL, Torlakovic E (2001)
Cultured anaplastic cell lines as immunocytochemistry controls: a comparison of ThinPrep-processed smears and conventional air-dried cytospins
Diagn Cytopathol, 25 (5), 303-8
DOI 10.1002/dc.2059, PubMed 11747220

Davidson B, Risberg B, Kristensen G, Kvalheim G, Emilsen E, Bjåmer A, Berner A (1999)
Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers
Virchows Arch, 435 (1), 43-9
DOI 10.1007/s004280050393, PubMed 10431845

Suo Z, Emilsen E, Tveit KM, Nesland JM (1998)
Type 1 protein tyrosine kinases in benign and malignant breast lesions
Histopathology, 33 (6), 514-21
DOI 10.1046/j.1365-2559.1998.00498.x, PubMed 9870145

Rye PD, Fodstad O, Emilsen E, Bryne M (1998)
Invasion potential and N-acetylgalactosamine expression in a human melanoma model
Int J Cancer, 75 (4), 609-14
DOI 10.1002/(sici)1097-0215(19980209)75:4<609::aid-ijc19>3.0.co;2-3, PubMed 9466664

Kareem BN, Karlsen F, Holm R, Hennig EM, Suo Z, Emilsen E, Hellesylt E, Nesland JM (1997)
A novel grid polymerase chain reaction (G-PCR) approach at ultrastructural level to detect target DNA in cell cultures and tissues
J Pathol, 183 (4), 486-93
DOI 10.1002/(SICI)1096-9896(199712)183:4<486::AID-PATH945>3.0.CO;2-D, PubMed 9496267

JOHANNESSEN JV, SOBRINHOSIMOES M, FINSETH I, EMILSEN E (1980)
SCANNING ELECTRON-MICROSCOPY OF THE HUMAN THYROID-GLAND - A SIMPLE METHOD TO REMOVE COLLOID
J. Submicrosc. Cytol. Pathol., 12 (2), 301-305